A Phase I Clinical Trial of Systemically Delivered NEMO Binding Domain Peptide in Dogs with Spontaneous Activated B-Cell like Diffuse Large B-Cell Lymphoma
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) is a common, aggressive and poorly chemoresponsive subtype of DLBCL, characterized by constitutive canonical NF-κB signaling. Inhibition of NF-κB signaling leads to apoptosis of ABC-DLBCL cell lines, suggesting targeted disruption of this pathway may have therapeutic relevance. The selective IKK inhibitor, NEMO Binding Domain (NBD) peptide effectively blocks constitutive NF-κB activity and induces apoptosis in ABC-DLBCL cells in vitro. Here we used a comparative approach to determine the safety and efficacy of systemic NBD peptide to inhibit constitutive NF-κB signaling in privately owned dogs with spontaneous newly diagnosed or relapsed ABC-like DLBCL. Malignant lymph nodes biopsies were taken before and twenty-four hours after peptide administration to determine biological effects. Intravenous administration of <2 mg/kg NBD peptide was safe and inhibited constitutive canonical NF-κB activity in 6/10 dogs. Reductions in mitotic index and Cyclin D expression also occurred in a subset of dogs 24 hours post peptide and in 3 dogs marked, therapeutically beneficial histopathological changes were identified. Mild, grade 1 toxicities were noted in 3 dogs at the time of peptide administration and one dog developed transient subclinical hepatopathy. Long term toxicities were not identified. Pharmacokinetic data suggested rapid uptake of peptide into tissues. No significant hematological or biochemical toxicities were identified. Overall the results from this phase I study indicate that systemic administration of NBD peptide is safe and effectively blocks constitutive NF-κB signaling and reduces malignant B cell proliferation in a subset of dogs with ABC-like DLBCL. These results have potential translational relevance for human ABC-DLBCL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561 · cited 1×
“Pet dogs that develop Non-Hodgkins Lymphoma (NHL) are recognized as a clinically relevant, spontaneous large animal model of the human disease [25,27–31].”
BackgroundStaudt, L. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000109 · Cited by 485
Nadjar, A., Bluthé, R.-M., May, M. J., Dantzer, R., & Parnet, P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300755 · Cited by 120 · cited 1×
“75 mg/kg to 20 mg/kg and have demonstrated that following intraperitoneal, intranasal, intracranial and topical administration NBD peptide has therapeutic effects at distant sites [15,17–19,40–44].”
BackgroundSelf-citationKiessling, M. K., Klemke, C. D., Kamiński, M. M., Galani, I. E., Krammer, P. H., & Gülow, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3221 · Cited by 115 · cited 1×
“NBD peptide also inhibits constitutive NF-kB activity in malignant cell lines derived from many different cancer types, including ABC-DLBCL resulting in increased sensitization to chemotherapeutic agents and increased apoptosis [21–26].”
Background
Cited by
The NF-κB Pathway and Cancer Stem Cells
Rinkenbaugh, A., & Baldwin, A. (2016) · Cells · doi:10.3390/cells5020016 · Cited by 260
Self-citationGardner, H. L., Fenger, J. M., & London, C. A. (2016) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-022114-110911 · Cited by 215
NEMO Links Nuclear Factor-κB to Human Diseases
Maubach, G., Schmädicke, A.-C., & Naumann, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.10.004 · Cited by 77
Targeting NF-κB Signaling for Multiple Myeloma
Wong, A. H.-H., Shin, E. M., Tergaonkar, V., & Chng, W.-J. (2020) · Cancers · doi:10.3390/cancers12082203 · Cited by 42
Metadata
- Authors
- Habineza Ndikuyeze, G., Gaurnier-Hausser, A., Patel, R., Baldwin, A. S., May, M. J., Flood, P., Krick, E., Propert, K. J., & Mason, N. J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-05-05
- Volume
- 9
- Issue
- 5
- Pages
- e95404
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2020572230
- Cited by
- 43
- References
- 4
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase I Clinical Trial of Systemically Delivered NEMO Binding Domain Peptide in Dogs with Spontaneous Activated B-Cell like Diffuse Large B-Cell Lymphoma. https://app.cochat.ai/papers/10.1371/journal.pone.0095404
- The paper
- Habineza Ndikuyeze, G., Gaurnier-Hausser, A., Patel, R., Baldwin, A. S., May, M. J., Flood, P., Krick, E., Propert, K. J., & Mason, N. J. (2014). A Phase I Clinical Trial of Systemically Delivered NEMO Binding Domain Peptide in Dogs with Spontaneous Activated B-Cell like Diffuse Large B-Cell Lymphoma. PLoS ONE. https://doi.org/10.1371/journal.pone.0095404
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.